Wei-de Zhong

List of Publications by Year
in descending order

126 papers	3,550 citations	109137 35 h-index	182168 51 g-index
130 all docs	130 docs citations	130 times ranked	5391 citing authors

#	Article	IF	Citations
1	Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis. Current Cancer Drug Targets, 2023, 23, 71-86.	0.8	3
2	CancerMIRNome: an interactive analysis and visualization database for miRNome profiles of human cancer. Nucleic Acids Research, 2022, 50, D1139-D1146.	6.5	49
3	Analysis of the Role of Comprehensive Treatment Model in the Treatment of Prostate Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-7.	0.7	1
4	Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism. Asian Journal of Andrology, 2022, .	0.8	2
5	Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts. Cancer Research, 2022, 82, 1832-1843.	0.4	13
6	Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 831329.	1.8	9
7	Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-51.	0.7	4
8	Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer. Disease Markers, 2022, 2022, 1-14.	0.6	1
9	Down-regulation of ACACA suppresses the malignant progression of Prostate Cancer through inhibiting mitochondrial potential. Journal of Cancer, 2021, 12, 232-243.	1.2	15
10	Disulfiramâ€copper activates chloride currents and induces apoptosis with tyrosine kinase in prostate cancer cells. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	4
11	TFEB Promotes Prostate Cancer Progression via Regulating ABCA2-Dependent Lysosomal Biogenesis. Frontiers in Oncology, 2021, 11, 632524.	1.3	14
12	The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer Proliferation. OncoTargets and Therapy, 2021, Volume 14, 3353-3366.	1.0	9
13	A HIF1Î±-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism. Journal of Experimental and Clinical Cancer Research, 2021, 40, 188.	3.5	27
14	Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer. Frontiers in Genetics, 2021, 12, 703210.	1.1	3
15	Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy. Frontiers in Immunology, 2021, 12, 735170.	2.2	31
16	Novel immuneâ€related signature for risk stratification and prognosis in prostatic adenocarcinoma. Cancer Science, 2021, 112, 4365-4376.	1.7	11
17	The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders. Translational Andrology and Urology, 2021, 10, 3579-3590.	0.6	1
18	Prediction of Biochemical Recurrence-Free Survival of Prostate Cancer Patients Leveraging Multiple Gene Expression Profiles in Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 632571.	1.3	11

#	Article	IF	Citations
19	HnRNP-L-regulated circCSPP1/miR-520h/EGR1 axis modulates autophagy and promotes progression in prostate cancer. Molecular Therapy - Nucleic Acids, 2021, 26, 927-944.	2.3	19
20	DCUN1D1 promotes tumor progress in prostate cancer and its effect on DU145 in vitro. JPMA the Journal of the Pakistan Medical Association, 2021, 71, 1-16.	0.1	1
21	Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer. Pathology Research and Practice, 2020, 216, 152732.	1.0	10
22	Clinicopathological characteristics of localized prostate cancer in younger men agedÂâ‰Â50Âyears treated with radical prostatectomy in the PSA era: A systematic review and metaâ€analysis. Cancer Medicine, 2020, 9, 6473-6484.	1.3	11
23	Inference of Chromosome-Length Haplotypes Using Genomic Data of Three or a Few More Single Gametes. Molecular Biology and Evolution, 2020, 37, 3684-3698.	3.5	11
24	Carbon Nanospheres Exert Antitumor Effects Associated with Downregulation of 4E-BP1 Expression on Prostate Cancer . International Journal of Nanomedicine, 2020, Volume 15, 5545-5559.	3.3	6
25	Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer . Cancer Management and Research, 2020, Volume 12, 6149-6163.	0.9	16
26	The study of multiple diagnosis models of human prostate cancer based on Taylor database by artificial neural networks. Journal of the Chinese Medical Association, 2020, 83, 471-477.	0.6	0
27	GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate. Cancer Research, 2020, 80, 2150-2162.	0.4	43
28	ARNTâ€dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer. Molecular Carcinogenesis, 2020, 59, 897-907.	1.3	10
29	Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer. BMC Cancer, 2020, 20, 289.	1.1	11
30	Genome-Scale CRISPR-Cas9 Transcriptional Activation Screening in Metformin Resistance Related Gene of Prostate Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 616332.	1.8	9
31	KIF4A: A potential biomarker for prediction and prognostic of prostate cancer. Clinical and Investigative Medicine, 2020, 43, E49-59.	0.3	4
32	Functional classification of prostate cancerâ€‘associated miRNAs through CRISPR/Cas9â€‘mediated gene knockout. Molecular Medicine Reports, 2020, 22, 3777-3784.	1.1	12
33	Increased intracellular Clâ¯ concentration mediates Trichomonas vaginalis-induced inflammation in the human vaginal epithelium. International Journal for Parasitology, 2019, 49, 697-704.	1.3	9
34	Offsetting Expression Profiles of Prognostic Markers in Prostate Tumor vs. Its Microenvironment. Frontiers in Oncology, 2019, 9, 539.	1.3	7
35	miRâ€‘505 suppresses prostate cancer progression by targeting NRCAM. Oncology Reports, 2019, 42, 991-1004.	1.2	10
36	HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer. Pathology Research and Practice, 2019, 215, 152464.	1.0	23

#	Article	IF	Citations
37	TRIB1 induces macrophages to M2 phenotype by inhibiting IKB-zeta in prostate cancer. Cellular Signalling, 2019, 59, 152-162.	1.7	39
38	Modeling the Complex Exposure History of Smoking in Predicting Bladder Cancer. Epidemiology, 2019, 30, 458-465.	1.2	7
39	Expression of PDâ€L1 in tumorâ€associated nerves correlates with reduced CD8⁺ tumorâ€associated lymphocytes and poor prognosis in prostate cancer. International Journal of Cancer, 2019, 144, 3099-3110.	2.3	45
40	Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer. Oncology Letters, 2019, 18, 6697-6703.	0.8	12
41	Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer. Cell Death and Disease, 2018, 9, 301.	2.7	20
42	GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC. Bioinformatics, 2018, 34, 2515-2517.	1.8	195
43	miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression. Oncology Reports, 2018, 39, 1658-1670.	1.2	33
44	Expression of aromatase in tumor related stroma is associated with human bladder cancer progression. Cancer Biology and Therapy, 2018, 19, 175-180.	1.5	10
45	Increased intracellular Clâ¯ concentration promotes ongoing inflammation in airway epithelium. Mucosal Immunology, 2018, 11, 1149-1157.	2.7	46
46	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European Urology, 2018, 73, 322-339.	0.9	130
47	Increased expression of immediate early response gene 3 protein promotes aggressive progression and predicts poor prognosis in human bladder cancer. BMC Urology, 2018, 18, 82.	0.6	13
48	Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNAâ€30d in patient with prostate cancer. Journal of Cellular Biochemistry, 2018, 119, 7245-7255.	1.2	13
49	Overexpression of TPX2 is associated with progression and prognosis of prostate cancer. Oncology Letters, 2018, 16, 2823-2832.	0.8	31
50	Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer. International Journal of Biological Macromolecules, 2018, 118, 599-609.	3.6	19
51	Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer. Cancer Research, 2018, 78, 4459-4470.	0.4	84
52	SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer. Current Cancer Drug Targets, 2018, 18, 894-904.	0.8	19
53	High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. International Urology and Nephrology, 2017, 49, 817-823.	0.6	42
54	Role of GPR30 in estrogen-induced prostate epithelial apoptosis and benign prostatic hyperplasia. Biochemical and Biophysical Research Communications, 2017, 487, 517-524.	1.0	14

#	Article	IF	Citations
55	miR-30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein. Molecular Medicine Reports, 2017, 16, 2431-2438.	1.1	22
56	Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer. Tumor Biology, 2017, 39, 101042831770392.	0.8	13
57	Identification of Potent Chloride Intracellular Channel Protein 1 Inhibitors from Traditional Chinese Medicine through Structure-Based Virtual Screening and Molecular Dynamics Analysis. BioMed Research International, 2017, 2017, 1-10.	0.9	9
58	Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer. PLoS ONE, 2017, 12, e0178613.	1.1	14
59	Mitochondrion-associated protein peroxiredoxin 3 promotes benign prostatic hyperplasia through autophagy suppression and pyroptosis activation. Oncotarget, 2017, 8, 80295-80302.	0.8	22
60	Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. OncoTargets and Therapy, 2016, 9, 2211.	1.0	87
61	Effect of alpha1-blockers on stentless ureteroscopic lithotripsy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 101-106.	0.7	5
62	Supine Versus Prone Position in Percutaneous Nephrolithotomy for Kidney Calculi: A Meta-Analysis. Journal of Endourology, 2016, 30, 754-763.	1.1	95
63	BCL9, a coactivator for Wnt/Î²-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncology Letters, 2016, 11, 2001-2008.	0.8	31
64	Association between allergic conditions and risk of prostate cancer: A Prisma-Compliant Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 35682.	1.6	9
65	E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer. International Journal of Oncology, 2016, 48, 1650-1658.	1.4	44
66	Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer. Biomedicine and Pharmacotherapy, 2016, 78, 116-120.	2.5	22
67	Synergistic anticancer effect of exogenous wild-typep53gene combined with 5-FU in human colon cancer resistant to 5-FUin vivo. World Journal of Gastroenterology, 2016, 22, 7342.	1.4	17
68	Preoperative evaluation of renal artery anatomy using computed tomography angiography to guide the superselective clamping of renal arterial branches during a laparoscopic partial nephrectomy. Experimental and Therapeutic Medicine, 2015, 10, 139-144.	0.8	7
69	Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. BMC Urology, 2015, 15, 90.	0.6	34
70	Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients. Molecular Carcinogenesis, 2015, 54, 1194-1204.	1.3	41
71	Value of CT angiography in reducing the risk of hemorrhage associated with mini-percutaneous nephrolithotomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 690-696.	0.7	5
72	Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia. Scientific World Journal, The, 2015, 2015, 1-5.	0.8	8

#	Article	IF	Citations
73	Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer. Oncology Reports, 2015, 33, 2648-2654.	1.2	8
74	Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. International Journal of Molecular Medicine, 2015, 35, 966-972.	1.8	38
75	Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer. Human Pathology, 2015, 46, 295-303.	1.1	61
76	Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer. Medical Oncology, 2015, 32, 373.	1.2	24
77	miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer. Clinical Cancer Research, 2015, 21, 4922-4934.	3.2	121
78	Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Human Pathology, 2015, 46, 820-826.	1.1	26
79	Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1. International Journal of Biological Macromolecules, 2015, 81, 615-623.	3.6	17
80	MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer. Tumor Biology, 2015, 36, 1983-1991.	0.8	44
81	CC Chemokine Ligand 18 Correlates with Malignant Progression of Prostate Cancer. BioMed Research International, 2014, 2014, 1-10.	0.9	43
82	MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. International Journal of Cancer, 2014, 135, 541-550.	2.3	114
83	Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence- free survival in patients with prostate cancer. OncoTargets and Therapy, 2014, 7, 137.	1.0	18
84	Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer. Medical Oncology, 2014, 31, 820.	1.2	40
85	Elevated levels of mitochondrionâ€associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer. Cancer, 2014, 120, 1228-1236.	2.0	39
86	MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Molecular Biology Reports, 2014, 41, 2779-2788.	1.0	34
87	Expression of SOCSs in human prostate cancer and their association in prognosis. Molecular and Cellular Biochemistry, 2013, 381, 51-59.	1.4	40
88	Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation. Molecular Biology Reports, 2013, 40, 3799-3805.	1.0	14
89	Percutaneous nephrolithotomy for renal stones following failed extracorporeal shockwave lithotripsy: different performances and morbidities. Urolithiasis, 2013, 41, 165-168.	1.2	8
90	Analysis of genetic aberrations on chromosomal region 8q21â€“24 identifies E2F5 as an oncogene with copy number gain in prostate cancer. Medical Oncology, 2013, 30, 465.	1.2	22

#	Article	IF	Citations
91	MicroRNA-335 Acts as a Candidate Tumor Suppressor in Prostate Cancer. Pathology and Oncology Research, 2013, 19, 529-537.	0.9	38
92	Aberrant activation of Hedgehog pathway in Nasopharyngeal carcinoma. Clinical and Experimental Medicine, 2013, 13, 315-322.	1.9	10
93	Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 654-659.	3.3	57
94	Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics, 2013, 14, 757.	1.2	42
95	An Integrative Proteomics and Interaction Network-Based Classifier for Prostate Cancer Diagnosis. PLoS ONE, 2013, 8, e63941.	1.1	26
96	A 32-gene risk index: a new prognostic approach for prostate cancer progression. Asian Journal of Andrology, 2013, 15, 590-591.	0.8	0
97	MicroRNAâ€23b downregulates peroxiredoxin III in human prostate cancer. FEBS Letters, 2012, 586, 2451-2458.	1.3	45
98	SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer, 2012, 12, 248.	1.1	69
99	Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population. Medical Oncology, 2012, 29, 1972-1984.	1.2	24
100	Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Medical Oncology, 2012, 29, 2877-2888.	1.2	44
101	Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clinical and Translational Oncology, 2012, 14, 190-196.	1.2	16
102	Expression of Hedgehog Pathway Components is Associated with Bladder Cancer Progression and Clinical Outcome. Pathology and Oncology Research, 2012, 18, 349-355.	0.9	41
103	Expression of CD147 is associated with prostate cancer progression. International Journal of Cancer, 2012, 130, 300-308.	2.3	44
104	Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells. Medical Oncology, 2011, 28, 878-887.	1.2	6
105	Classical and Alternative Nuclear Factor-ÎºB Pathways: A Comparison among Normal Prostate, Benign Prostate Hyperplasia and Prostate Cancer. Pathology and Oncology Research, 2011, 17, 873-878.	0.9	6
106	CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma. Clinical and Experimental Medicine, 2010, 10, 153-158.	1.9	17
107	Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Medical Oncology, 2010, 27, 145-151.	1.2	18
108	Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer. Cancer Epidemiology, 2010, 34, 478-482.	0.8	12

#	Article	IF	Citations
109	Expression and Clinical Significance of CD147 in Genitourinary Carcinomas. Journal of Surgical Research, 2010, 160, 260-267.	0.8	40
110	Inhibition of Proliferation, Invasion, and Migration of Prostate Cancer Cells by Downregulating Elongation Factor-1Î± Expression. Molecular Medicine, 2009, 15, 363-370.	1.9	18
111	Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Seminars in Cancer Biology, 2009, 19, 338-343.	4.3	55
112	Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine, 2009, 35, 112-117.	1.1	30
113	Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer. Medical Oncology, 2009, 26, 303-308.	1.2	16
114	CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer. Pathology and Oncology Research, 2009, 15, 369-374.	0.9	36
115	CD147 and VEGF Expression in Advanced Renal Cell Carcinoma and Their Prognostic Value. Cancer Investigation, 2009, 27, 788-793.	0.6	53
116	Proton magnetic resonance spectroscopy in neonates with hypoxic-ischemic injury and its prognostic value. Translational Research, 2008, 152, 225-232.	2.2	29
117	CD147, MMP-1, MMP-2 and MMP-9 Protein Expression as Significant Prognostic Factors in Human Prostate Cancer. Oncology, 2008, 75, 230-236.	0.9	89
118	Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18513-18518.	3.3	70
119	Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clinical and Investigative Medicine, 2008, 31, 8.	0.3	83
120	Protective effect of ganoderan on renal damage in rats with chronic glomerulonephritis. Clinical and Investigative Medicine, 2008, 31, 212.	0.3	7
121	Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomedicine and Pharmacotherapy, 2007, 61, 534-539.	2.5	32
122	cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chinese Medical Journal, 2006, 119, 570-3.	0.9	1
123	A clinical study on prostate cancer diagnosis with cDNA macroarray. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2005, 17, 66-70.	0.7	0
124	Clinical significance of telomerase activity and peripheral venous blood CK-20 expression in bladder transitional cell carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2003, 15, 132-135.	0.7	0
125	Treatment of lower urethral calculi with extracorporeal shock-wave lithotripsy and pneumatic ureteroscopic lithotripsy: a comparison of effectiveness and complications. Chinese Medical Journal, 2003, 116, 1001-3.	0.9	2
126	Functionalized Silver Nanoparticles Enhance Therapeutic Effect of Paclitaxel for Prostate Cancer Therapy by Arresting the Cellular Cycle and Producing ROS. Nano, 0, , .	0.5	4